Vortex Launches Clinical Study to Transform Cancer Monitoring with Live-Cell Liquid Biopsy Technology
Key Insights
Vortex Liquid Biopsy Solutions (search) has launched a clinical study with The Doctors Laboratory (search) to assess how its live-cell liquid biopsy technology can transform cancer (search) monitoring and treatment.
The technology captures intact, living circulating tumor cells (search) directly from whole blood within about an hour, offering a less invasive alternative to traditional surgical biopsies.
The study will begin in Q4 2025 at TDL's London facilities and will use AI-driven analytics from strategic partner AxonDx (search) to interpret captured cells for personalized cancer (search) care.
Vortex Liquid Biopsy Solutions (search) has announced a major clinical study with The Doctors Laboratory (search) (TDL) Trials aimed at transforming cancer (search) monitoring and treatment through its innovative live-cell liquid biopsy technology. The research will take place at TDL's advanced facilities in the HALO Building, London, focusing on assessing how effectively the technology can capture and analyze live circulating tumor cells (search) (CTCs) from patient blood samples.
Revolutionary Approach to Cancer Monitoring
Traditional tumor biopsies require surgically removing tissue, a procedure that is invasive, disruptive and unsuitable for many patients. Vortex's liquid biopsy platform offers a less invasive alternative by isolating intact, living cancer (search) cells directly from whole blood within about an hour. These cells are captured at high purity and high yield, preserving their natural state for detailed analysis.
"Cancer (search) is a leading cause of death worldwide and while treatments have advanced significantly, clinicians still need better ways to track how the disease is responding in real time," said Dr Paul Reeves, managing director of Vortex. "This study is an important step in showing how live circulating tumour cells can give doctors that insight, helping to refine treatment choices and improve outcomes for patients."
Clinical Study Design and Timeline
The study will involve a cohort of patients with progressive cancer (search) and is expected to begin in Q4 2025. The research will focus on how effectively Vortex's liquid biopsy technology can capture and analyze live circulating tumor cells (search) directly from blood samples, enabling detailed characterization of biomarkers (search) to inform cancer progression and treatment response.
The ability to analyze live CTCs could offer clinicians a clearer, more immediate picture of how a patient's cancer (search) is evolving. Biomarker characterization, mutation tracking and treatment-response monitoring – all carried out on cells collected through a simple blood draw – could help guide therapy selection far more dynamically than traditional methods.
Advanced Analytics Integration
The study will be supported by AxonDx (search), Vortex's strategic partner, which will apply its AI-driven analytical tools to interpret the captured cells, allowing for deeper biological insights that could help clinicians monitor disease progression more precisely. This integration of live-cell isolation and advanced computational analysis represents an emerging frontier in personalized cancer (search) care.
"This collaboration brings together clinical excellence and cutting-edge technology to address a growing global health need," said Dr Nigel Brookes, non-executive chairman of Vortex. "Partnering with TDL, a leader in clinical laboratory services, allows us to generate the real-world evidence needed to bring liquid biopsy testing into routine clinical use and make precision medicine more accessible worldwide."
Potential Clinical Impact
By capturing living cancer (search) cells in their natural, unaltered state, researchers and clinicians can observe how tumors behave and respond to treatment in near real time. This could enable earlier detection of therapeutic resistance, more accurate tracking of disease progression and more confident clinical decision-making.
If successful, the study could contribute to a shift towards routine clinical adoption of liquid biopsy testing, reducing reliance on surgical procedures and giving clinicians faster, more actionable insights. For patients, this may translate into more personalized treatment plans and improved outcomes.
The partnership between Vortex, TDL and AxonDx (search) represents the pursuit of next-generation cancer (search) diagnostics and highlights the growing potential of live-cell liquid biopsy to reshape modern oncology.